# SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct05576480/  
OnCo record `nct05576480` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of penpulimab and cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by Ruijin Hospital, now recruiting.

## Summary

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT05576480 by Ruijin Hospital, with a registry enrolment figure of 55 participants, started 2023-02-06 and due to reach its primary completion in 2025-10. Interventions recorded: Short-course radiotherapy; Penpulimab; CAPEOX; TME surgery. Conditions listed: Rectal Cancer; Locally Advanced. Primary outcome: Pathological complete remission rate (pCR). Colorectal eligibility wording from the registry: "* Patients with pathologically confirmed rectal adenocarcinoma, assessed by MRI as mid-low rectal cancer (the lower border of the tumor is less than 10cm from the anal verge), clinical stage II-III (cT1-2N1-2M0 or T3-4N0-2M0) according to the 8th Edition of AJCC Cancer Staging Manual". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: SPARC
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05576480
- Phase: 2
- Setting: Efficacy and Safety of Short-course Radiotherapy Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of Microsatellite Stable Locally Advanced Rectal Cancer: a Single-centre, Single-arm, Phase 2 Study
- Sponsor: Ruijin Hospital
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT05576480: https://clinicaltrials.gov/study/NCT05576480

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Penpulimab](https://onco.cc/drugs/penpulimab/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05576480.json